Neonatal diabetes mellitus: a model for personalized medicine
- PMID: 20434356
- PMCID: PMC2914172
- DOI: 10.1016/j.tem.2010.03.004
Neonatal diabetes mellitus: a model for personalized medicine
Abstract
Neonatal diabetes mellitus occurs in approximately 1 out of every 100,000 live births. It can be either permanent or transient, and recent studies indicate that is likely to have an underlying genetic cause, particularly when diagnosed before 6 months of age. Permanent neonatal diabetes is most commonly due to activating mutations in either of the genes encoding the two subunits of the ATP-sensitive potassium channel. In most of these patients, switching from insulin to oral sulfonylurea therapy leads to improved metabolic control, as well as possible amelioration of occasional associated neurodevelopmental disabilities. It remains to be determined what is the most appropriate treatment of other causes. The diagnosis and treatment of neonatal diabetes, therefore, represents a model for personalized medicine.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
References
-
- Eide SA, et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study) Diabet Med. 2008;25:775–781. - PubMed
-
- Murphy R, et al. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4:200–213. - PubMed
-
- Hattersley A, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2009;10 12:33–42. - PubMed
-
- Schwartzman J, et al. Diabetes mellitus in infants under one year of age; report of a case and review of the literature. Am J Dis Child. 1947;74:587–606. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
